Here’s our fortnightly wrap of all the news driving ASX health stocks.

It’s been a largely positive two week in the ASX small and mid-cap healthcare space, with 67 companies gaining ground and 49 losing it. Another 16 companies were flat and we had one debutant that we’ll get to later.
 

Code Company Price % return since Feb 3 %YTD return % return since 31/12/19 MktCap
1AD Adalta 18.5 48.0 119.7 48.0 $47,809,291
1ST 1St Group 3.5 16.7 -39.7 2.9 $15,710,825
4DX 4Dmedical 195 -5.8 -19.8 $346,105,648
AC8 Auscann Grp Hlgs 18 0.0 -33.3 -7.7 $58,653,761
ACR Acrux 17.5 -7.9 2.9 6.1 $49,407,663
ACW Actinogen Medical 2.2 4.8 -27.6 4.8 $35,468,317
ADO Anteotech 26 40.5 815.6 147.6 $523,641,076
ADR Adherium 2.2 0.0 -29.0 -21.4 $14,271,516
AGH Althea Group 53.75 14.4 45.3 23.6 $140,369,844
AHC Austco Healthcare 9.8 -2.0 -6.7 -1.0 $27,850,517
AHK Ark Mines 3.4 0.0 0.0 0.0 $1,778,920
ALC Alcidion Group 21 -2.3 -4.5 13.5 $203,092,281
ALT Analytica 0.3 -25.0 0.0 0.0 $10,558,837
AMT Allegra Orthopaedics 30 -10.4 114.3 -14.3 $31,860,057
ANP Antisense Therapeut. 19.5 5.4 174.6 50.0 $114,811,188
APH AP Hemp 49 8.9 276.9 44.1 $27,762,142
ARX Aroa Biosurgery 120.5 -1.2 4.8 $354,857,169
AT1 Atomo Diagnostics 28.5 -3.4 -6.6 $114,209,294
ATH Alterity Therap 4.3 19.4 152.9 38.7 $89,612,717
ATX Amplia Therapeutics 28.5 5.6 208.1 18.8 $29,084,190
AVE Avecho Biotech 2.5 0.0 614.3 -13.8 $41,571,262
BD1 Bard1 Life Sciences 325 470.2 209.5 377.9 $295,325,756
BIT Biotron 7.3 0.0 -45.9 -6.4 $53,346,886
BNO Bionomics 26.5 82.8 332.5 82.8 $172,783,174
BOT Botanix Pharma 13.25 -22.1 47.2 6.0 $131,374,180
BPH BPH Energy 20.5 -2.4 2263.7 376.7 $83,001,885
BWX BWX 397 -2.9 -13.0 -3.4 $558,175,992
BXN Bioxyne 1.2 0.0 -7.7 0.0 $7,681,745
CAJ Capitol Health 28.5 -1.7 7.3 3.6 $292,822,541
CAN Cann Group 75 15.4 -33.3 27.1 $209,545,966
CBL Control Bionics 73 -7.6 -22.3 $36,085,450
CDX Cardiex 8.7 8.8 278.3 55.4 $76,722,474
CDY Cellmid 9.8 -2.0 -48.4 -10.9 $12,721,230
CGS Cogstate 102.5 -11.4 111.3 -6.8 $168,535,948
CHM Chimeric Therapeutic 30.5 0.0 $56,985,000
CMP Compumedics 45.5 -6.2 -48.3 -9.0 $81,494,956
CP1 Cannpal Animal 18 0.0 44.0 5.9 $17,228,125
CPH Creso Pharma 23 9.5 91.7 27.8 $212,921,938
CTE Cryosite 26.5 -33.8 430.0 -32.9 $12,183,486
CYC Cyclopharm 282 2.5 152.7 12.8 $257,994,297
CYP Cynata Therapeutics 68 2.3 -36.3 -0.7 $98,144,467
DOC Doctor Care Anywhere 128 0.8 6.7 $229,169,496
DVL Dorsavi 3.5 2.9 35.6 -14.6 $12,594,549
DXB Dimerix 29 0.0 100.0 23.4 $56,394,175
EXL Elixinol Global 23 15.0 -54.1 31.4 $73,749,810
EYE Nova EYE Medical 34 3.0 -20.3 -4.2 $48,853,287
FFC Farmaforce 9 0.0 0.0 0.0 $11,589,388
GLH Global Health 40 -5.9 185.7 -14.9 $16,839,328
GSS Genetic Signatures 173.5 -6.7 48.3 -13.7 $257,174,543
GTG Genetic Technologies 1.15 15.0 15.0 53.3 $99,156,494
HCT Holista CollTech 7.1 -1.4 -54.2 -1.4 $19,549,785
HXL Hexima 15 -6.3 -50.8 -18.9 $18,055,861
IBX Imagion Biosys 20 14.3 638.3 37.9 $178,064,289
ICR Intelicare Holdings 28.5 14.0 18.8 $9,893,840
ICS ICSGlobal 196 -0.3 9.0 -7.1 $20,627,077
IDT IDT Australia 21 5.0 50.0 13.5 $50,048,179
IHL annex Healthcare 25 56.3 323.7 61.3 $270,919,222
IMC Immuron 25.5 24.4 82.1 10.9 $55,675,416
IMM Immutep 41 0.0 3.8 -1.2 $272,464,620
IMU Imugene 11 12.2 233.3 10.0 $547,183,357
IPD Impedimed 14.5 20.8 43.1 16.0 $182,010,529
IVX Invion 1.1 22.2 10.0 10.0 $55,377,923
JHC Japara Healthcare Lt 77.5 12.3 -14.1 25.0 $213,797,862
JHL Jayex Healthcare 5 25.0 127.3 28.2 $9,262,699
KZA Kazia Therapeutics 125 -2.3 126.9 7.8 $157,076,999
LBT LBT Innovations 11 4.8 -29.0 -10.2 $31,079,880
LCT Living Cell Tech. 2.1 40.0 10.5 50.0 $12,571,702
LSH Lifespot Health 12.5 8.7 267.9 62.3 $20,216,035
M7T Mach7 Tech 151.5 2.4 80.2 21.2 $366,315,639
MDC Medlab Clinical 32 3.2 4.9 33.3 $95,089,728
MDR Medadvisor 36 -4.0 -30.4 1.4 $129,411,780
MEB Medibio 1 11.1 14.4 25.0 $17,268,733
MEM Memphasys 11 4.8 74.6 10.0 $87,373,996
MMJ MMJ Group Hlds 14 16.7 21.7 12.0 $32,193,558
MVF Monash IVF Group 77.5 -1.9 -13.6 -1.3 $305,863,349
MVP Medical Developments 627 -4.3 -42.6 -6.1 $449,680,080
MX1 Micro-X 36.5 1.4 86.0 2.8 $166,188,326
MXC Mgc Pharmaceuticals 6.7 157.7 148.1 168.0 $173,847,048
NC6 Nanollose 12.5 -3.8 134.2 131.5 $15,489,382
NEU Neuren Pharmaceut. 138 -7.4 -49.6 7.4 $160,451,351
NOX Noxopharm 83 14.5 248.1 69.4 $216,827,148
NSB Neuroscientific 23.5 4.4 46.9 -6.0 $22,626,208
NTI Neurotech Intl 6.7 34.0 737.5 48.9 $34,223,180
NXS Next Science 117.5 -1.3 -43.5 -6.0 $142,590,482
NYR Nyrada . 37.5 10.3 78.6 56.3 $28,254,965
OCC Orthocell 57.5 7.5 18.6 27.8 $108,535,552
OIL Optiscan Imaging 19 72.7 475.8 81.0 $95,483,248
ONE Oneview Healthcare 9.3 14.8 -21.9 106.7 $38,466,264
ONT 1300 Smiles 780 14.4 28.1 15.9 $166,932,607
OPT Opthea 180.75 -5.4 -46.8 -5.9 $611,172,146
OSL Oncosil Medical 11.5 -8.0 -33.0 -4.2 $92,844,479
OSP Osprey Med 1.9 -9.5 18.8 -13.6 $32,466,939
OSX Osteopore 47.5 -5.0 -23.4 -8.7 $36,287,577
OVN Oventus Medical 21 -4.5 -62.8 -10.6 $34,817,732
PAA Pharmaust 10.5 0.0 0.0 0.0 $33,256,642
PAB Patrys 2.6 0.0 45.4 8.3 $48,815,343
PAL Palla Pharma 54 -12.2 -35.7 -33.3 $69,901,127
PAR Paradigm Bio. 261 -6.1 -36.7 2.4 $596,256,007
PBP Probiotec 221 0.0 -6.8 -7.9 $172,619,493
PCK Pahek 7.2 4.3 -40.0 -6.5 $78,876,336
PGC Paragon Care 27 12.5 3.8 20.0 $91,229,029
PIQ Proteomics Int Lab 106.5 43.9 222.7 34.0 $110,151,169
PNV Polynovo 250 -4.6 -18.6 -35.6 $1,679,163,632
PSQ Pacific Smiles Grp 266 1.9 42.8 4.3 $400,675,586
PTX Prescient 12.5 19.0 140.4 86.6 $76,866,361
PXS Pharmaxis 8.5 -1.2 -26.1 -8.6 $34,559,340
PYC PYC Therapeutics 13.5 0.0 112.5 -8.5 $428,075,024
RAC Race Oncology 287 34.7 720.0 64.0 $380,609,093
RAP Resapp Health 6.5 -4.4 -72.9 -23.5 $51,552,125
RCE Recce Pharmaceutical 104.5 2.0 90.0 -0.9 $189,365,237
RGS Regeneus 11 0.0 77.4 -12.0 $33,031,282
RHT Resonance Health 19.5 14.7 -4.9 -18.8 $85,234,376
RHY Rhythm Biosciences 138.5 14.5 1698.7 58.3 $277,159,865
RNO Rhinomed 11.5 -23.3 -28.1 -28.1 $31,726,142
RSH Respiri 13.5 8.0 58.8 3.8 $101,127,711
S66 Star Combo 27.5 -8.3 -52.6 -16.7 $37,045,929
SCU Stemcell United 2.7 58.8 80.0 42.1 $22,688,658
SDI SDI 76 -3.8 -21.8 -3.2 $91,526,458
SHG Singular Health 47 $25,731,750
SOM SomnoMed 186 -2.1 -34.1 -11.4 $158,070,292
SUD Suda Pharmaceuticals 4.9 8.9 3.3 22.5 $18,410,154
SVA Simavita 1.6 -5.9 -30.4 0.0 $22,279,497
TD1 Tali Digital 4.6 12.2 9.5 -2.1 $35,737,550
THC THC Global Grp 25.5 8.5 -33.8 8.5 $48,311,522
TLX Telix Pharmaceutical 419 -1.2 155.5 10.8 $1,163,682,086
TRU Truscreen 9.3 -19.1 $34,835,160
UBI Universal Biosensors 43 -11.3 145.7 -1.1 $76,337,987
VBS Vectus Biosystems 133.5 0.4 130.2 11.3 $41,310,289
VHT Volpara Health Tech 151.5 -1.9 -11.7 5.6 $368,998,049
VLS Vita Life Sciences.. 99.5 4.7 75.0 -0.5 $51,648,894
VTI Vision Tech, 2 17.6 -48.7 -20.0 $19,874,511
ZLD Zelira Therapeutics 8 2.6 37.9 -13.0 $94,825,837
ZNO Zoono Group 74.5 -24.7 -59.9 -43.3 $129,649,039

Bard1 Life Sciences (ASX:BD1) has been by far the biggest gainer since February 3, with shares in the cancer diagnostic company up 470 per cent through yesterday afternoon to $3.25.

At the beginning of the month, BD1 shares were changing hands for less than 60c – and had been in decline for the past 12 months – but have rocketed higher in recent days after the company released data showing its cancer detection tech works against breast cancer and ovarian cancer.

“Obviously we’ve accomplished a lot in a week,” Bard1 chief executive Dr Learnne Hinch joked to Stockhead.

In reality, not much has changed with the company recently, she added. Staff have been hard at work for months “building the foundations for our success” — developing Bard1’s cancer-detecting blood tests and integrating technology from Sienna Cancer Diagnostics after last year’s merger.

“We think we have been substantially undervalued, and the market is finally recognising our value,” she said.

The company is focused on early cancer detection through simple, cost-effective blood tests that could save lives.

“Our multi-product pipeline covers some of the world’s most common and deadliest cancers in multi-billion dollar markets for ovarian, breast, prostate, and pancreatic cancers,” Dr Hinch wrote in an email.

Bard1 has a number of potential value inflection points coming up, including registering its hTERT cancer blood test in South Korea this quarter, and launching its exosome purification platform next quarter.

“We’ve got a lot going on as a business, it’s going be an exciting year for Bard1 and shareholders,” Dr Hinch said.


 

MGC, Bionomics, Cryosite

The second spot belongs to MGC Pharmaceuticals (ASX:MXC), whose shares soared after MGC became the first cannabis company to list on the London Stock Exchange.

MGC shares have retreated a bit after touching 8c earlier this week, trading for 6.7c yesterday afternoon, still up 157.7 per cent for the fortnight.

Bionomics (ASX:BNO) was in third with an 82 per cent gain, to 26.5c. The company held a $16 million capital raising last week at 14.5c a share to fund a phase 2b clinical trial of its drug candidate to treat post-traumatic stress disorder (PTSD).

On the flip side, Cryosite (ASX:CTE) shares are down by a third, to 26.5c, over the fortnight.

The clinical trials company has released no news, but ASX documents show that a major shareholder has been selling down its holdings.

Blood and tissue bank Cell Care Australia sold over half a million shares over the period, reducing its stake in Cryosite to 18.6 per cent, from 19.7 per cent.
 

New entrant

Meanwhile, medical imaging company Singular Health (ASX:SHG) has done well after joining the small-cap healthcare space last Friday after a $6 million IPO at 20c a share.

Its shares closed Wednesday at 45c, and changed hands on Tuesday for as much as 55c.